Searchable abstracts of presentations at key conferences on calcified tissues

ba0004p191 | (1) | ICCBH2015

Evolution of bone quality and quantity in patients suffering from Duchenne Muscular Dystrophy

Del Rio Luis , Di Gregorio Silvana , Winzenrieth Renaud

The aim of the study is to evaluate, across time, if a bone microarchitectural texture modification exists or not and to evaluate its associations with other bone and body composition parameters.16 Spanish children suffering from DMD with a mean age 9.7±3.0 years and height and weight z-score of −0.76 and 0.16 SD were included in the study. Spine DXA scans and body composition scans were obtained using a GE Lunar Prodigy at baseline, ...

ba0006p058 | (1) | ICCBH2017

The relationship between maternal and child bone density in Nigerian children with and without nutritional rickets

Bommersbach Tanner , Fischer Philip , Pettifor John , Thacher Tom

Objective: To determine the relationship between maternal and child bone density in a cohort of mothers and their children with and without rickets.Methods: Using a case-control design without matching, areal forearm bone mineral density (aBMD) was measured in 52 and 135 Nigerian children with and without rickets, respectively, and their mothers. The metaphyseal site was located at the site of minimal bone density of the distal radius and ulna. The diaph...

ba0007lb4 | (1) | ICCBH2019

Impact of pubertal suppression on body composition and bone density in adolescents with gender dysphoria

Shepherd Sheila , Dewantoro Dixon , Ahmed Syed Faisal , Gerasimidis Kostas , Mason Avril , Shaikh Guftar , Wong SC , Kyriakou Andreas

Introduction: Pubertal suppression with gonadotrophin releasing hormone (GnRH) analogue is introduced after onset of puberty in adolescents with gender dysphoria (GD). As puberty is a critical period for bone accrual and changes in body composition, alterations in body composition and bone mass may be observed during treatment.Methods: Thirty-eight adolescents (32/38 assigned females at birth) with GD had dual energy X-ray absorptiometry (DXA) prior to s...

ba0002p161 | (1) | ICCBH2013

Autoimmune hepatitis and bone density in children

Vai Silvia , Nebbia Gabriella , Bianchi Maria Luisa

Autoimmune hepatitis (AIH) is an immune-mediated chronic inflammatory disease of the liver of unknown origin, that suddenly appears in previously healthy, normally growing children. Standard therapy is long-term prednisone, aimed at avoiding progression to cirrhosis. Considering the inflammatory origin of the disease and the long-term steroid therapy, negative consequences for bone health can be expected, but no data on this complication have been published until now.<p cl...

ba0002p63 | (1) | ICCBH2013

Bone status of Indian children and adolescents with type 1 diabetes mellitus

Parthasarathy Lavanya , Khadilkar Anuradha , Ekbote Veena , Chiplonkar Shashi , Mughal Zulf , Khadilkar Vaman

Objective: Type 1 diabetes mellitus (TIDM) has been shown to adversely affect bone health in children. Hence, objective was to assess bone health status of children with T1DM, and to assess relationship between bone status and disease duration.Methods: Bone mineral content for total body (less head) (TBBMC) and lumbar spine was measured by DXA in 47 (25 boys) children with T1DM. Z-scores for TBBMC for bone area (TBBA), TBBA for height, lean body...

ba0001oc5.6 | Treatment of osteoporosis | ECTS2013

Testosterone replacement has a substantial benefit on bone mass, fracture incidence, libido, and sexual activities in male cardiac transplant patients: a 5-year randomized prospective controlled trial

Wagner Doris , Prenner Guenther , Dobnig Harald , Dimai Hans Peter , Pieber Thomas , Pilz Stefan , Tomaschitz Andreas , Amrein Karin , Fahrleitner-Pammer Astrid

Hypogonadism is common in cardiac transplant (CTX) patients and exerts negative effects on bone but also on libido and quality of life.We investigated whether testosterone replacement therapy (TRT) has any positive effects on bone mass, fracture incidence, and quality of sex life when administered in addition to ibandronate (IBN) in hypogonadal CTX recipients. 52 male patients entered the study and received IBN (quarterly 2 μg i.v.). 60% of the pati...

ba0006oc10 | (1) | ICCBH2017

Inadequate vitamin D status adversely affects trabecular bone mineral density in 14–18 year old adolescents

Smith Taryn , Tripkovic Laura , Damsgaard Camilla , Molgaard Christian , Hennessy Aine , Dowling Kirsten , Cashman Kevin , Kiely Mairead , Lanham-New Susan , Hart Kathryn

We have previously shown a high prevalence of vitamin D inadequacy (serum 25-hydroxyvitamin D (S25(OH)D) <50 nmol/l) in adolescents (14–18 years) in the UK (51°N)(1). It is well recognised that vitamin D deficiency (S25(OH)D <25 nmol/l) increases the risk of rickets and impaired growth in adolescents, however the optimal vitamin D status for bone health is debated. The aim of this study was to investigate the effects of vitamin D status on bone hea...

ba0001pp128 | Calciotropic and phosphotropic hormones and mineral metabolism | ECTS2013

Mass spectrometric immunoassay for intact parathyroid hormone: correlation with immunoassay and application to clinical samples

Couchman L , Taylor D , Krystans B , Lopez M , Prakash A , Sarracino D , Garces A , Vogelsang M , Peterman S , Vadali G , Robinson S , Moniz C

Introduction: Parathyroid hormone (PTH) measurement is of use in i) differential diagnosis of hypercalcaemia and ii) patients with renal impairment at risk of bone disease. PTH immunoassays are complicated by cross-reactivity with truncated (inactive) variant forms, which accumulate in patients with renal impairment. PTH assay variability is a critical governance issue in renal medicine, suggesting an MS-based reference method is required.Aim: To develop...

ba0001pp435 | Osteoporosis: treatment | ECTS2013

Denosumab's dynamic CTX profile is maintained over 6 years of treatment: first 3 years of the FREEDOM extension study

Roux C , McClung MR , Franchimont N , Adami S , Ebeling PR , Reid IR , Resch H , Weryha G , Daizadeh N , Wang A , Wagman RB , Eastell R

Denosumab (DMAb) has a unique profile of bone resorption inhibition: CTX decreases rapidly by 3 days and inhibition is released at the end of the 6-month dosing interval, when DMAb serum levels decrease (McClung NEJM 2006). The dynamic CTX inhibition profile is not curtailed by continued treatment. In the 3-year FREEDOM study, CTX values at 6 months were influenced by baseline CTX values and days since the 1st injection (Eastell JBMR 2011). With 3 additional ...

ba0002oc7 | Biology | ICCBH2013

The PPP6R3/LRP5 locus influences lean mass in children of different ethnic background and highlights pleiotropic effects and muscle–bone interactions

Medina-Gomez Carolina , Heppe Denise , Estrada Karol , Hofman Albert , Hsu Yi-Hsiang , Karasik David , Jaddoe Vincent , Zillikens M Carola , Uitterlinden Andre G , Rivadeneira Fernando

Aim: Lean and bone mass have considerably high phenotypic and genetic correlations with a shared heritability estimate ranging between 30 and 40% in adults. A genome-wide association study (GWAS) on total body lean mass and a bivariate GWAS on lean mass and BMD were ran in a cohort of children to identify genes with pleiotropic effects on muscle mass and peak bone mass attainment.Methods: Subjects are part of the Generation R study, a prospective multiet...